ATYR Strangle Strategy
ATYR (aTyr Pharma, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis.
ATYR (aTyr Pharma, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $51.7M, a beta of 0.54 versus the broader market, a 52-week range of 0.395-7.29, average daily share volume of 2.4M, a public-listing history dating back to 2015, approximately 56 full-time employees. These structural characteristics shape how ATYR stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.54 indicates ATYR has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on ATYR?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current ATYR snapshot
As of June 30, 2026, spot at $0.59, ATM IV 254.30%, IV rank 27.23%, expected move 72.91%. The strangle on ATYR below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this strangle structure on ATYR specifically: ATYR IV at 254.30% is on the cheap side of its 1-year range, which favors premium-buying structures like a ATYR strangle, with a market-implied 1-standard-deviation move of approximately 72.91% (roughly $0.43 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ATYR expiries trade a higher absolute premium for lower per-day decay. Position sizing on ATYR should anchor to the underlying notional of $0.59 per share and to the trader's directional view on ATYR stock.
ATYR strangle setup
The ATYR strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ATYR near $0.59, the first option leg uses a $0.62 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ATYR chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ATYR shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $0.62 | N/A |
| Buy 1 | Put | $0.56 | N/A |
ATYR strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
ATYR strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on ATYR. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on ATYR
Strangles on ATYR are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ATYR chain.
ATYR thesis for this strangle
The market-implied 1-standard-deviation range for ATYR extends from approximately $0.16 on the downside to $1.02 on the upside. A ATYR long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current ATYR IV rank near 27.23% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ATYR at 254.30%. As a Healthcare name, ATYR options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ATYR-specific events.
ATYR strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ATYR positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ATYR alongside the broader basket even when ATYR-specific fundamentals are unchanged. Always rebuild the position from current ATYR chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on ATYR?
- A strangle on ATYR is the strangle strategy applied to ATYR (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ATYR stock trading near $0.59, the strikes shown on this page are snapped to the nearest listed ATYR chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ATYR strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ATYR strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 254.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ATYR strangle?
- The breakeven for the ATYR strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ATYR market-implied 1-standard-deviation expected move is approximately 72.91%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on ATYR?
- Strangles on ATYR are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ATYR chain.
- How does current ATYR implied volatility affect this strangle?
- ATYR ATM IV is at 254.30% with IV rank near 27.23%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.